We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

73 hedge funds and large institutions have $19.2M invested in Aevi Genomic Medicine Inc in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

399% more call options, than puts

Call options by funds: $2.74M | Put options by funds: $549K

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

0% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 21

4% less funds holding

Funds holding: 76 → 73 (-3)

78% less capital invested

Capital invested by funds: $88.1M → $19.2M (-$68.9M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
73
Holders Change
-3
Holders Change %
-3.95%
% of All Funds
1.82%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
21
Reduced
21
Closed
9
Calls
$2.74M
Puts
$549K
Net Calls
+$2.19M
Net Calls Change
-$4.05M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.13M
2
BBA
Baker Bros. Advisors
New York
+$3.34M
3
Goldman Sachs
Goldman Sachs
New York
+$880K
4
2L
22NW LP
Washington
+$701K
5
RFCA
R&F Capital Advisors
New York
+$381K

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$15.2M
2
Jennison Associates
Jennison Associates
New York
-$8.91M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.52M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.94M
5
OM
Opaleye Management
Massachusetts
-$1.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
51
Bank of America
North Carolina
$13K +$4.66K +1,031 +18%
Deutsche Bank
52
Deutsche Bank
Germany
$12K -$36.1K -7,981 -55%
SO
53
STRS Ohio
Ohio
$9K – – –
PVH
54
Psagot Value Holdings
Israel
$7K -$2.4K -530 -12%
Victory Capital Management
55
Victory Capital Management
Texas
$7K – – –
Royal Bank of Canada
56
Royal Bank of Canada
Ontario, Canada
$6K -$2.47K -545 -15%
LA
57
Legacy Advisors
Pennsylvania
$4K – – –
PA
58
Perceptive Advisors
New York
$2K -$1.32M -292,520 -100%
Creative Planning
59
Creative Planning
Kansas
$2K -$40.7K -9,000 -90%
BKA
60
Brick & Kyle Associates
Pennsylvania
$2K – – –
TWA
61
TCI Wealth Advisors
Arizona
$2K – – –
IWM
62
IHT Wealth Management
Illinois
$2K +$2.26K +500 +100%
AIP
63
Ameritas Investment Partners
Nebraska
$2K +$5.88K +1,299 New
MAM
64
Meeder Asset Management
Ohio
$1K -$8.43K -1,863 -76%
AG
65
Advisor Group
Arizona
$1K – – –
IA
66
IFP Advisors
Florida
$1K – – –
KTC
67
Kistler-Tiffany Companies
Pennsylvania
$1K – – –
LTFS
68
Ladenburg Thalmann Financial Services
Florida
$1K – – –
BNP Paribas Financial Markets
69
BNP Paribas Financial Markets
France
$63 +$154 +34 New
BC
70
Broadfin Capital
New York
– -$15.2M -3,370,306 Closed
Jennison Associates
71
Jennison Associates
New York
– -$8.91M -1,720,838 Closed
T. Rowe Price Associates
72
T. Rowe Price Associates
Maryland
– -$3.94M -760,167 Closed
CC
73
Casdin Capital
New York
– -$1.94M -375,000 Closed
OAM
74
Oxford Asset Management
United Kingdom
– -$249K -47,995 Closed
Squarepoint
75
Squarepoint
New York
– -$161K -31,152 Closed
1 2
3
4

GNMX Hedge Fund Activity: Q1 2017 in Review

73 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2017, worth a combined $19.2M — down 78% from $88.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GNMX positions and 9 closed out — a net gain of 1 holder — while 21 added to existing stakes and 21 trimmed.

The largest buyer was BlackRock, adding an estimated $9.13M. The largest seller was Broadfin Capital, exiting entirely with an estimated $15.2M sold.

  • 73 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2017, down from 76 in Q4 2016.
  • Funds reported $19.2M of Aevi Genomic Medicine Inc stock for Q1 2017, down 78% quarter-over-quarter.
  • 10 funds opened new Aevi Genomic Medicine Inc positions in Q1 2017 and 9 closed out, a net change of +1 holder.
  • The largest Aevi Genomic Medicine Inc buyer in Q1 2017 was BlackRock, an estimated $9.13M added.
  • The largest Aevi Genomic Medicine Inc seller in Q1 2017 was Broadfin Capital, an estimated $15.2M sold.

Based on aggregated 13F filings for Q1 2017.